Erectile Dysfunction (ED) Drugs Market
Erectile Dysfunction (ED) Drugs Market (Drug - Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Press Release :
Global Erectile Dysfunction (ED) Drugs Market: Snapshot
The increasing prevalence of erectile dysfunction is boosting the global erectile dysfunction (ED) market. Erectile dysfunction can be caused due to various factors such as aging, cardiovascular diseases, spinal cord injuries, hypertension, side-effects of medicines consumed, and others. The effective and first line of treatment for ED comprises the oral medication such as Oral phosphodiesterase type 5 (PDE5) inhibitor.
Male sexual abilities decreases post 50 years of age coupled with rising incidence of ED. The elderly population is susceptible to the erectile dysfunction which is boosting the need for novel drugs for the treatment of this incapability. Moreover, some psychological and physical changes, coupled with growing incidences of hormonal alteration, are leading to increasing the erectile dysfunction which is propelling growth of the global erectile dysfunction (ED) drugs market.
A study by New England Research Institutes, the patients suffering from erectile dysfunction was 152 million in 1995 and is expected to increase to 322 million in 2025. This rise in cases of erectile dysfunction is due to the growing geriatric population. This growing number is creating the need for the novel treatments and likely to propel the growth of the erectile dysfunction (ED) drugs market.
According to the TMR, the global erectile dysfunction (ED) drugs market was valued at US$4.35 Bn in 2016 and is expected to decline with 3.2% CAGR over the forecast period from 2018 to 2026 to reach a value of US$ 2.87 Bn by the end of 2026.
Growth Witnessed in Retail Segment to Boost Market
On the basis of the drug, the global erectile dysfunction (ED) drugs market is segmented into viagra, cialis, staxyn/levitra, and stendra/spedra. Of these, cialis (tadalafil) dominated the global market for erectile dysfunction (ED) drugs followed by Viagra. Viagra segment was dominating the market, however, patent expiry affected its business. Additionally, patent expiry of Cialis in 2017 affected the growth of the market drastically.
On the basis of the distribution channel, the global erectile dysfunction (ED) drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Of these, the retail pharmacies segment is expected to dominate the global erectile dysfunction (ED) drugs market owing to its easy availability of erectile dysfunction drugs at retail stores. The hospital pharmacies segments are accounting for the second-leading share and expected to expand with higher CAGR over the forecast period.
High Awareness Aids Expansion of Market in North America
On the basis of region, the global erectile dysfunction (ED) drugs market is segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Of these, North America dominated the global market for erectile dysfunction (ED) drugs in 2016 followed by Europe. This growth in the market is attributable to the high awareness and the growing research and development activities. Additionally, factors such as the presence of favorable medical reimbursement policies, the high prevalence of erectile dysfunction, and a growing geriatric population are fuelling the growth of dysfunction drugs market presence in North America. The market in the Middle East and Africa is offering lucrative opportunities owing to growing awareness about the presence of drugs for ED. However, the market in Asia Pacific is expected to expand with impressive CAGR owing to growth initiatives for increasing awareness about dysfunction drugs.
Some of the key players operating in the erectile dysfunction (ED) drugs market are Pfizer, Inc., Eli Lilly and Company, Dong-A ST Co., Ltd., VIVUS, INC., and Bayer AG. The global erectile dysfunction (ED) drugs market has consolidated vendor landscape. The aforementioned players are accounting for major shares in the global market for erectile dysfunction (ED) drugs. These manufacturers are increasingly launching new products in the international market to fulfill the unmet demands from patients for the treatment of erectile dysfunction.
Erectile Dysfunction (ED) Drugs Market - Overview
This report studies the current as well as future prospects of the global erectile dysfunction (ED) drugs market. Stakeholders of the market include companies and intermediaries engaged in the manufacture, commercialization, and marketing of therapeutic drugs for the treatment of erectile dysfunction, as well as new players planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global erectile dysfunction drugs market with respect to the leading segments based on drug class, distribution channel, and region.
The global erectile dysfunction drugs market has been segmented based on drug, distribution channel, and region. In terms of drug, the market has been classified into Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and others. Based on distribution channel, the global erectile dysfunction drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of erectile dysfunction. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.
The overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the global erectile dysfunction drugs market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global erectile dysfunction drugs market.
Geographically, the global erectile dysfunction drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thereby presenting a thorough examination of the overall competitive scenario of the global erectile dysfunction drugs market.
Major players operating in the global erectile dysfunction drugs market are Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, VIVUS, Inc., SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Teva Pharmaceutical Industries Ltd.
The global erectile dysfunction drugs market has been segmented as follows: